An effective treatment for HER-2-positive breast cancer with brain metastases: Tucatinib

HER-2-positive metastatic breast cancer patients may, in a significant proportion of cases, develop brain metastases during their disease course. For brain metastases developing in these patients, locally targeted treatments (surgery, stereotactic radiosurgery and/or whole-brain radiotherapy) are used alongside systemic therapy to manage the disease. However, this treatment approach may change: a study presented at ASCO 2020 points toward a change in management. Tucatinib in combination with trastuzumab and capecitabine has been shown to provide clinical benefit in these patients, according to scientific evidence from the HER2CLIMB clinical trial's subgroup analysis.
The HER2CLIMB study and tucatinib
HER2CLIMB, involving a total of 612 patients, is a multicenter, randomized-controlled, double-blind phase-III clinical trial. In 2019, the San Antonio Breast Symposium featured the study assessing results of tucatinib combined with trastuzumab and capecitabine in 612 patients with locally advanced or metastatic HER2-positive breast cancer previously treated with trastuzumab, pertuzumab and ado-trastuzumab emtansine (T-DM1). These results subsequently provided evidence for the FDA's approval of tucatinib on 17 April 2020 (see here).
Subgroup analysis design and results
- Of the 612 patients enrolled in HER2CLIMB, 291 had brain metastases or a history of brain metastases at baseline (198 in the tucatinib arm and 93 in the control arm).
- At baseline, the number of patients with treated, stable brain metastases was 80 in the tucatinib arm and 37 in the control arm. Actively progressing brain metastases were present in 118 patients in the tucatinib arm and 56 in the control arm. Nearly all patients in both arms (approximately 97% in each arm) had concurrent disease outside the brain. As can be seen, the distribution of disease characteristics was consistent with the overall study randomization (random allocation) ratio of 2:1.
- The proportion of patients with 1-year central nervous system (CNS) progression-free survival (PFS, the time from the new treatment until disease worsening or progression) was 40.2% (95% CI; 29.5%–50.6%) in the tucatinib arm and 0% in the control arm. Median CNS-PFS was 9.9 months in the tucatinib arm and 4.2 months in the control arm.
- The risk of intracranial (within the skull) disease progression or death was 68% lower in the tucatinib arm (HR, 0.32; 95% CI; 0.22–0.48).
- The risk of death was 42% lower in the tucatinib arm (HR for OS, 0.58; 95% CI; 0.40–0.85). Median overall survival was 18.1 months in patients receiving tucatinib and 12 months in the control group.
- Intracranial treatment response (ORR-IC) was higher in the tucatinib arm than in the control arm. In the tucatinib arm, complete ORR-IC was seen in 5.5% of patients and partial ORR-IC in 43.6%.
- Tucatinib showed benefits in CNS progression-free survival and median overall survival in patients with either active or stable brain metastases. However, median overall survival alone did not reach statistical significance in patients with stable brain metastases (estimated 1-year OS in patients with stable metastases was 67.6% in the tucatinib arm and 55.6% in the control arm [HR, 0.88; 95% CI; 0.45–1.70; p= 0.696]).
What the study means
In summary, this subgroup analysis showed that in patients previously treated with (T-DM1, pertuzumab, trastuzumab) who had HER-2-positive breast cancer with brain metastases, adding tucatinib to transtuzumab and capecitabine doubled the intracranial treatment response rate, reduced the risk of CNS progression or death by 2 out of 3, and approximately halved the risk of death. Tucatinib became the first treatment agent whose antitumor activity in patients with the above characteristics was demonstrated in a randomized controlled clinical trial.
How does tucatinib work?

HER-2 (human epidermal growth factor receptor-2) is a tyrosine kinase receptor belonging to the EGFR (epidermal growth factor receptors) family. Members of this family include EGFR (HER 1/erbB1), HER2 (neu/erbB2), HER-3 (erbB3) and HER-4 (erbB4). When different ligands (molecules carrying the relevant signal outside the cell) bind to these cell-membrane receptors, the receptors dimerize and activate a series of intracellular signaling molecules. HER-2 can form a dimer (a paired structure) with another HER-2 (homodimer) or with HER-3 (heterodimer) on the cell membrane.
Trastuzumab and pertuzumab, which are currently used, are monoclonal antibodies developed against this receptor (Trastuzumab acts by binding to a HER-2, whereas Pertuzumab disrupts receptor dimerization). This blocks pathways mediated by these receptors and also generates an antibody-dependent cellular cytotoxicity–immune response. Ado-trastuzumab-emtansine is a large-molecule drug in which the cytotoxic drug DM1 is attached to trastuzumab.
There are also drugs that disrupt the activity of tyrosine kinase receptors. Tucatinib is a reversible, small-molecule inhibitor that acts with high specificity on the HER2 receptor tyrosine kinase. Its high specificity for HER-2 compared with other epidermal growth factors in the EGFR family is important (it is more than 1000 times as active for HER-2 as for other EGFRs). By inhibiting HER-2 activity, tucatinib stops downstream intracellular signaling pathways such as MAPK and PI3K/AKT from functioning. This reduces uncontrolled tumor cell division, survival capacity and the likelihood of metastasis.
Sources
Kulukian, A., et al. (2020). "Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models." Mol Cancer Ther 19(4): 976-987.
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.